TITLE

An update on psychopharmacologic medication: What

AUTHOR(S)
Sweeney, Dwight P.; Forness, Steven R.
PUB. DATE
September 1997
SOURCE
Intervention in School & Clinic;Sep97, Vol. 33 Issue 1, p4
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Discusses the potential uses and abuses of psychopharmacologic therapy with children or adolescents displaying learning, emotional, or behavioral disorders. Classes of medications commonly used to treat learning and behavioral disorders; Indications and contraindications of various medications; Side effects encountered in the most frequently prescribed medications.
ACCESSION #
9710055445

 

Related Articles

  • NON-PSYCHOTROPIC DRUGS AND SLEEP. Idzikowski, Chris; Shapiro, Colin M. // BMJ: British Medical Journal (International Edition);4/24/93, Vol. 306 Issue 6885, p1118 

    Examines the physiological effect of psychotropic drugs on human health. Association between sleep and non-psychotropic drugs; Importance of pharmacokinetic profiles of any drugs; Evaluation of the pharmacological action of the drug.

  • Targets of your daily CA(2)ppuccino. Spencer, Timothy // Nature Neuroscience;Jan2012, Vol. 15 Issue 1, p12 

    The article focuses on the physiological effects of caffeine on humans and refers to studies which explains the cellular and molecular mechanism of caffeine which makes it a psychoactive stimulant.

  • Medicines for the Mind. Goff, Karen Goldberg // Insight on the News;06/19/2000, Vol. 16 Issue 23, p27 

    Reports on the safety aspects of a selective serotonin-reuptake-inhibitor antidepressant. Side-effects of these type of drugs; Claim of drug manufacturers, physicians and patients that have used the drugs about its long-term effects.

  • Psychopharmacologic Treatment: A Note on Classroom Effects. Forness, Steven R.; Kavale, Kenneth A. // Journal of Learning Disabilities;Mar1988, Vol. 21 Issue 3, p144 

    Discusses issues in child psychopharmacology, highlighting the four major classes of psychotropic medication along with certain methodological concerns in both research and classroom intervention. Areas of psychopharmacology; Research on antidepressants or mood altering medication; Effects of...

  • Psychopharmacology for the Clinician. Wiens, Andrew // Journal of Psychiatry & Neuroscience;Mar2000, Vol. 25 Issue 2, p198 

    Presents a question-and answer advisory on the application of psychopharmacology by clinicians. Effect of grapefruit juice on psychotropic medications; Details of treatment of a patient with depression; Mechanism of action of fluvoxamine.

  • Craving.  // Encyclopedic Reference of Molecular Pharmacology;2004, p273 

    A reference entry for the term "craving" is presented. The World Health Organization defines this term as the desire to experience the effects of a previously experience pscyhoactive substance. However, there is debate on whether this term describes a physiological, subjective or behavioral state.

  • Locomotor response to MDMA is attenuated in knockout mice lacking the 5-HT[sub 1B] receptor. Scearce-Levie, Kimberly; Viswanathan, Sandya S.; Hen, R. // Psychopharmacology;1999, Vol. 141 Issue 2, p154 

    Abstract 3,4-Methylenedioxymethamphetamine (MDMA) is a psychoactive drug of abuse which is increasingly popular in human recreational drug use. In rats, the drug has been shown to stimulate locomotion while decreasing exploratory behavior. MDMA acts as an indirect agonist of serotonin (5-HT)...

  • Psychopharmacology and memory. Glannon, W. // Journal of Medical Ethics;Feb2006, Vol. 32 Issue 2, p74 

    Psychotropic and other drugs can alter brain mechanisms regulating the formation, storage, and retrieval of different types of memory. These include "off label" uses of existing drugs and new drugs designed specifically to target the neural bases of memory. This paper discusses the use of...

  • Constipation caused by opioids treated with MTX.  // Hospice Management Advisor;Oct2008, Vol. 13 Issue 10, p118 

    The article provides information on opioid-induced bowel dysfunction (OBD) which is caused by opioids treated with methylnaltrexone (MTX). It states that MTX is a mu receptor antagonist which does not induce withdrawal symptoms in patients undertaking chronic opioid therapy. Pilot trials also...

  • Divergent Plasticity of Prefrontal Cortex Networks. Moghaddam, Bita; Homayoun, Houman // Neuropsychopharmacology;Jan2008, Vol. 33 Issue 1, p42 

    The ‘executive’ regions of the prefrontal cortex (PFC) such as the dorsolateral PFC (dlPFC) and its rodent equivalent medial PFC (mPFC) are thought to respond in concert with the ‘limbic’ regions of the PFC such as the orbitofrontal (OFC) cortex to orchestrate behavior...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics